Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis

This nonrandomized clinical trial examines the safety and efficacy of oral upadacitinib in the treatment of patients with severe immune checkpoint inhibitor–related dermatitis.

Corresponding Author: Shixiu Wu, MD, PhD, Quzhou People’s Hospital, No. 100 Minjiang Ave, Quzhou, Zhejiang 324000, China (wushixiu@medmail.com.cn).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.